 Paul Maroni
Concepts (341)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prostatic Neoplasms | 38 | 2023 | 921 | 4.130 |
Why?
| | Prostatectomy | 8 | 2019 | 98 | 1.600 |
Why?
| | Testicular Neoplasms | 7 | 2023 | 96 | 1.200 |
Why?
| | Urology | 3 | 2020 | 46 | 0.920 |
Why?
| | Neoplasms, Germ Cell and Embryonal | 3 | 2023 | 62 | 0.750 |
Why?
| | Embolism | 1 | 2021 | 43 | 0.740 |
Why?
| | Urethra | 1 | 2021 | 48 | 0.740 |
Why?
| | Laser Therapy | 1 | 2021 | 100 | 0.690 |
Why?
| | Androgen Antagonists | 3 | 2016 | 69 | 0.680 |
Why?
| | Clinical Trials as Topic | 1 | 2020 | 931 | 0.520 |
Why?
| | Kidney Medulla | 2 | 2005 | 29 | 0.490 |
Why?
| | Early Detection of Cancer | 5 | 2023 | 328 | 0.490 |
Why?
| | Neoadjuvant Therapy | 2 | 2021 | 304 | 0.420 |
Why?
| | Male | 55 | 2023 | 55554 | 0.410 |
Why?
| | Urination Disorders | 1 | 2011 | 11 | 0.380 |
Why?
| | Prostate-Specific Antigen | 8 | 2020 | 151 | 0.380 |
Why?
| | Prostate | 7 | 2023 | 156 | 0.360 |
Why?
| | Oxalates | 2 | 2008 | 10 | 0.330 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2014 | 1214 | 0.330 |
Why?
| | Neoplasm Grading | 5 | 2021 | 242 | 0.310 |
Why?
| | Adenocarcinoma | 3 | 2022 | 795 | 0.300 |
Why?
| | Humans | 58 | 2023 | 114623 | 0.300 |
Why?
| | Radiotherapy, Adjuvant | 2 | 2018 | 182 | 0.280 |
Why?
| | Neoplasm Staging | 7 | 2021 | 1167 | 0.270 |
Why?
| | Clinical Competence | 1 | 2012 | 893 | 0.250 |
Why?
| | Kidney Tubules, Collecting | 1 | 2005 | 25 | 0.250 |
Why?
| | Oxalic Acid | 1 | 2004 | 4 | 0.240 |
Why?
| | Brachytherapy | 2 | 2016 | 103 | 0.240 |
Why?
| | Urinary Bladder Neoplasms | 2 | 2021 | 196 | 0.230 |
Why?
| | Aged | 21 | 2021 | 19061 | 0.200 |
Why?
| | Middle Aged | 20 | 2021 | 26719 | 0.200 |
Why?
| | Surveys and Questionnaires | 3 | 2017 | 4620 | 0.200 |
Why?
| | Paraganglioma | 1 | 2022 | 47 | 0.190 |
Why?
| | Adrenal Gland Neoplasms | 1 | 2022 | 81 | 0.190 |
Why?
| | Cell Hypoxia | 2 | 2015 | 220 | 0.190 |
Why?
| | Cation Transport Proteins | 1 | 2022 | 123 | 0.180 |
Why?
| | Prolactin | 3 | 1997 | 96 | 0.180 |
Why?
| | Adaptor Proteins, Vesicular Transport | 2 | 1997 | 45 | 0.180 |
Why?
| | Risk Assessment | 4 | 2020 | 2967 | 0.180 |
Why?
| | Orchiectomy | 3 | 2016 | 57 | 0.180 |
Why?
| | Magnetic Resonance Imaging, Interventional | 1 | 2020 | 20 | 0.180 |
Why?
| | Salvage Therapy | 2 | 2018 | 127 | 0.170 |
Why?
| | Stromal Cells | 1 | 2019 | 96 | 0.160 |
Why?
| | Proanthocyanidins | 1 | 2019 | 8 | 0.160 |
Why?
| | Biflavonoids | 1 | 2019 | 8 | 0.160 |
Why?
| | Hospitals | 2 | 2023 | 581 | 0.160 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2018 | 858 | 0.160 |
Why?
| | Catechin | 1 | 2019 | 23 | 0.160 |
Why?
| | Euterpe | 1 | 2018 | 5 | 0.160 |
Why?
| | Anthocyanins | 1 | 2019 | 29 | 0.160 |
Why?
| | Nomograms | 1 | 2019 | 41 | 0.160 |
Why?
| | Androgens | 3 | 2009 | 167 | 0.160 |
Why?
| | Grape Seed Extract | 1 | 2019 | 41 | 0.160 |
Why?
| | Digital Rectal Examination | 1 | 2018 | 10 | 0.150 |
Why?
| | Urinary Tract Infections | 1 | 2019 | 134 | 0.150 |
Why?
| | Adaptor Proteins, Signal Transducing | 2 | 1997 | 367 | 0.150 |
Why?
| | Reagent Kits, Diagnostic | 1 | 2018 | 42 | 0.150 |
Why?
| | Antineoplastic Agents, Phytogenic | 1 | 2019 | 181 | 0.150 |
Why?
| | Surgical Wound Infection | 2 | 2019 | 248 | 0.140 |
Why?
| | Mitogen-Activated Protein Kinase Kinases | 1 | 1997 | 113 | 0.140 |
Why?
| | Neoplasm Metastasis | 5 | 2019 | 522 | 0.140 |
Why?
| | Proton Therapy | 1 | 2017 | 10 | 0.140 |
Why?
| | Biopsy, Needle | 2 | 2016 | 182 | 0.140 |
Why?
| | Liver | 4 | 1997 | 1634 | 0.140 |
Why?
| | Seminoma | 1 | 2017 | 17 | 0.140 |
Why?
| | Medical Oncology | 1 | 2019 | 229 | 0.140 |
Why?
| | Plant Extracts | 1 | 2018 | 154 | 0.140 |
Why?
| | Sertoli-Leydig Cell Tumor | 1 | 2016 | 8 | 0.140 |
Why?
| | Prognosis | 7 | 2019 | 3328 | 0.140 |
Why?
| | Radiology | 1 | 2019 | 141 | 0.140 |
Why?
| | Spectrum Analysis | 1 | 2016 | 81 | 0.130 |
Why?
| | Sex Cord-Gonadal Stromal Tumors | 1 | 2015 | 5 | 0.130 |
Why?
| | Radiotherapy, Conformal | 1 | 2015 | 68 | 0.130 |
Why?
| | Neoplastic Stem Cells | 1 | 2019 | 329 | 0.120 |
Why?
| | Lymphatic Metastasis | 3 | 2014 | 275 | 0.120 |
Why?
| | Genomics | 1 | 2019 | 635 | 0.120 |
Why?
| | Proto-Oncogene Proteins | 2 | 1997 | 608 | 0.120 |
Why?
| | Risk | 2 | 2015 | 812 | 0.120 |
Why?
| | Fluorodeoxyglucose F18 | 1 | 2015 | 113 | 0.120 |
Why?
| | Hypertension | 1 | 2022 | 1056 | 0.120 |
Why?
| | Cause of Death | 1 | 2016 | 361 | 0.120 |
Why?
| | Biopsy | 4 | 2023 | 1036 | 0.120 |
Why?
| | Extracellular Vesicles | 1 | 2015 | 83 | 0.120 |
Why?
| | Leydig Cell Tumor | 1 | 2014 | 8 | 0.110 |
Why?
| | Treatment Outcome | 7 | 2018 | 9084 | 0.110 |
Why?
| | Receptors, Adrenergic, alpha | 1 | 2013 | 28 | 0.110 |
Why?
| | Priapism | 1 | 2013 | 10 | 0.110 |
Why?
| | Adrenergic alpha-Antagonists | 1 | 2013 | 29 | 0.110 |
Why?
| | Optics and Photonics | 1 | 2014 | 41 | 0.110 |
Why?
| | Cytochrome P-450 CYP3A Inhibitors | 1 | 2013 | 18 | 0.110 |
Why?
| | Triglycerides | 1 | 2015 | 467 | 0.110 |
Why?
| | Spectrometry, Fluorescence | 1 | 2014 | 157 | 0.110 |
Why?
| | Proline | 1 | 2013 | 72 | 0.110 |
Why?
| | Matrix Metalloproteinase 9 | 2 | 2010 | 119 | 0.100 |
Why?
| | Neoplasm Invasiveness | 4 | 2016 | 442 | 0.100 |
Why?
| | Signal Transduction | 4 | 2004 | 4509 | 0.100 |
Why?
| | Telephone | 1 | 2013 | 152 | 0.100 |
Why?
| | Drug Interactions | 1 | 2013 | 338 | 0.100 |
Why?
| | Survival Rate | 4 | 2017 | 1644 | 0.100 |
Why?
| | Attitude of Health Personnel | 1 | 2019 | 975 | 0.100 |
Why?
| | Cell Line | 3 | 2008 | 2635 | 0.100 |
Why?
| | Postoperative Complications | 2 | 2019 | 2128 | 0.100 |
Why?
| | Lymph Nodes | 1 | 2014 | 419 | 0.100 |
Why?
| | Aged, 80 and over | 6 | 2020 | 6344 | 0.090 |
Why?
| | Urothelium | 1 | 2011 | 33 | 0.090 |
Why?
| | Prostatic Hyperplasia | 1 | 2011 | 38 | 0.090 |
Why?
| | Epithelial Cells | 2 | 2008 | 950 | 0.090 |
Why?
| | Oxygen | 1 | 2015 | 854 | 0.090 |
Why?
| | Neoplastic Cells, Circulating | 1 | 2011 | 59 | 0.090 |
Why?
| | Mitogen-Activated Protein Kinase 1 | 4 | 2008 | 164 | 0.090 |
Why?
| | Decision Making | 1 | 2017 | 782 | 0.090 |
Why?
| | Carcinogenesis | 2 | 2022 | 177 | 0.090 |
Why?
| | Glucose | 1 | 2015 | 896 | 0.090 |
Why?
| | Combined Modality Therapy | 2 | 2016 | 1121 | 0.090 |
Why?
| | Counseling | 1 | 2013 | 342 | 0.090 |
Why?
| | Proto-Oncogene Proteins c-ets | 1 | 2010 | 51 | 0.090 |
Why?
| | Survival Analysis | 2 | 2016 | 1211 | 0.090 |
Why?
| | Spinal Fractures | 1 | 2011 | 75 | 0.090 |
Why?
| | Survivors | 1 | 2013 | 411 | 0.090 |
Why?
| | Mitogen-Activated Protein Kinase 3 | 3 | 2008 | 146 | 0.080 |
Why?
| | Carcinoma | 1 | 2011 | 198 | 0.080 |
Why?
| | Lymph Node Excision | 2 | 2014 | 139 | 0.080 |
Why?
| | Lymphatic Diseases | 1 | 2009 | 17 | 0.080 |
Why?
| | Cystitis | 1 | 2009 | 20 | 0.080 |
Why?
| | Age Factors | 4 | 2017 | 2894 | 0.080 |
Why?
| | Adult | 12 | 2020 | 30528 | 0.080 |
Why?
| | Focal Adhesion Protein-Tyrosine Kinases | 1 | 2008 | 27 | 0.080 |
Why?
| | Databases, Factual | 3 | 2019 | 1124 | 0.080 |
Why?
| | Logistic Models | 3 | 2019 | 1840 | 0.080 |
Why?
| | Cell Line, Tumor | 5 | 2015 | 2710 | 0.080 |
Why?
| | Patient Education as Topic | 1 | 2013 | 680 | 0.080 |
Why?
| | Patient Selection | 2 | 2018 | 641 | 0.080 |
Why?
| | Neoplasms, Hormone-Dependent | 1 | 2008 | 38 | 0.070 |
Why?
| | Proportional Hazards Models | 3 | 2016 | 1075 | 0.070 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2009 | 260 | 0.070 |
Why?
| | Societies, Medical | 1 | 2011 | 663 | 0.070 |
Why?
| | HSP70 Heat-Shock Proteins | 1 | 2008 | 61 | 0.070 |
Why?
| | Time Factors | 4 | 2014 | 6112 | 0.070 |
Why?
| | Young Adult | 6 | 2020 | 10455 | 0.070 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2009 | 249 | 0.070 |
Why?
| | Antineoplastic Agents, Hormonal | 1 | 2008 | 138 | 0.070 |
Why?
| | Image-Guided Biopsy | 2 | 2020 | 31 | 0.070 |
Why?
| | Diagnostic Imaging | 2 | 2022 | 275 | 0.070 |
Why?
| | Kidney Tubules, Proximal | 1 | 2008 | 113 | 0.070 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2008 | 332 | 0.070 |
Why?
| | Reactive Oxygen Species | 2 | 2009 | 531 | 0.070 |
Why?
| | Calcium-Calmodulin-Dependent Protein Kinases | 2 | 1997 | 172 | 0.070 |
Why?
| | Animals | 10 | 2022 | 31694 | 0.070 |
Why?
| | Radiotherapy Dosage | 2 | 2018 | 244 | 0.070 |
Why?
| | Follow-Up Studies | 4 | 2016 | 4411 | 0.070 |
Why?
| | Oxidative Stress | 2 | 2010 | 1076 | 0.070 |
Why?
| | Mice | 4 | 2022 | 14860 | 0.070 |
Why?
| | Ear, Inner | 1 | 2005 | 39 | 0.060 |
Why?
| | Isoflavones | 1 | 2005 | 16 | 0.060 |
Why?
| | History, 21st Century | 1 | 2006 | 159 | 0.060 |
Why?
| | Disease Progression | 2 | 2018 | 2380 | 0.060 |
Why?
| | Support Vector Machine | 2 | 2016 | 34 | 0.060 |
Why?
| | Body Fluids | 1 | 2005 | 58 | 0.060 |
Why?
| | Mitotic Index | 2 | 2015 | 26 | 0.060 |
Why?
| | Informed Consent | 1 | 2006 | 161 | 0.060 |
Why?
| | Mass Screening | 2 | 2015 | 1004 | 0.060 |
Why?
| | Kidney Neoplasms | 1 | 2009 | 327 | 0.060 |
Why?
| | United States | 5 | 2019 | 12176 | 0.060 |
Why?
| | Cell Count | 1 | 2005 | 303 | 0.060 |
Why?
| | Urinary Incontinence | 1 | 2005 | 56 | 0.060 |
Why?
| | Propensity Score | 2 | 2016 | 224 | 0.060 |
Why?
| | Growth | 1 | 2004 | 55 | 0.060 |
Why?
| | Cell Proliferation | 3 | 2019 | 2186 | 0.060 |
Why?
| | Receptors, Nicotinic | 1 | 2005 | 274 | 0.050 |
Why?
| | Multivariate Analysis | 2 | 2017 | 1430 | 0.050 |
Why?
| | Kaplan-Meier Estimate | 2 | 2016 | 811 | 0.050 |
Why?
| | Antineoplastic Agents | 1 | 2013 | 1879 | 0.050 |
Why?
| | Protein-Tyrosine Kinases | 2 | 1997 | 395 | 0.050 |
Why?
| | Urinary Bladder | 1 | 2004 | 162 | 0.050 |
Why?
| | Sensitivity and Specificity | 3 | 2016 | 1691 | 0.050 |
Why?
| | Transcriptional Regulator ERG | 1 | 2022 | 11 | 0.050 |
Why?
| | Rats, Wistar | 3 | 1997 | 368 | 0.050 |
Why?
| | Serine Endopeptidases | 1 | 2022 | 102 | 0.050 |
Why?
| | Testosterone | 2 | 2015 | 343 | 0.050 |
Why?
| | Cell Survival | 2 | 2019 | 1020 | 0.050 |
Why?
| | Adolescent | 5 | 2022 | 17831 | 0.050 |
Why?
| | Intestines | 1 | 2004 | 326 | 0.050 |
Why?
| | Src Homology 2 Domain-Containing, Transforming Protein 1 | 2 | 1997 | 10 | 0.050 |
Why?
| | Shc Signaling Adaptor Proteins | 2 | 1997 | 10 | 0.050 |
Why?
| | Biomarkers, Tumor | 2 | 2020 | 1040 | 0.050 |
Why?
| | Retrospective Studies | 4 | 2023 | 12542 | 0.050 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2022 | 179 | 0.040 |
Why?
| | Inflammation | 1 | 2010 | 2477 | 0.040 |
Why?
| | Rats | 5 | 2005 | 4958 | 0.040 |
Why?
| | Feeding Behavior | 1 | 2005 | 574 | 0.040 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2022 | 308 | 0.040 |
Why?
| | Reperfusion | 2 | 1996 | 36 | 0.040 |
Why?
| | Quality of Life | 2 | 2013 | 2353 | 0.040 |
Why?
| | Jagged-1 Protein | 1 | 2019 | 22 | 0.040 |
Why?
| | Zinc | 1 | 2022 | 260 | 0.040 |
Why?
| | Geography | 1 | 2019 | 177 | 0.040 |
Why?
| | Fruit and Vegetable Juices | 1 | 2018 | 11 | 0.040 |
Why?
| | Receptor, Notch1 | 1 | 2019 | 59 | 0.040 |
Why?
| | Positron Emission Tomography Computed Tomography | 1 | 2019 | 63 | 0.040 |
Why?
| | Spheroids, Cellular | 1 | 2019 | 56 | 0.040 |
Why?
| | Radiometry | 1 | 2018 | 42 | 0.040 |
Why?
| | Tissue Kallikreins | 1 | 2018 | 2 | 0.040 |
Why?
| | Kallikreins | 1 | 2018 | 30 | 0.040 |
Why?
| | Enzyme Activation | 4 | 2008 | 785 | 0.040 |
Why?
| | Janus Kinase 2 | 1 | 1997 | 31 | 0.040 |
Why?
| | Enzyme Induction | 1 | 1997 | 84 | 0.040 |
Why?
| | Carrier Proteins | 1 | 2022 | 695 | 0.040 |
Why?
| | Cells, Cultured | 1 | 2005 | 3881 | 0.040 |
Why?
| | MAP Kinase Kinase 1 | 1 | 1997 | 66 | 0.040 |
Why?
| | Prospective Studies | 2 | 2020 | 6217 | 0.040 |
Why?
| | Radiotherapy, Intensity-Modulated | 1 | 2018 | 124 | 0.040 |
Why?
| | Phenotype | 3 | 2010 | 2796 | 0.040 |
Why?
| | Tumor Cells, Cultured | 1 | 2019 | 849 | 0.040 |
Why?
| | National Cancer Institute (U.S.) | 1 | 2017 | 40 | 0.040 |
Why?
| | Health Care Surveys | 1 | 2019 | 539 | 0.030 |
Why?
| | Ultrasonography | 1 | 2020 | 633 | 0.030 |
Why?
| | Female | 7 | 2021 | 59466 | 0.030 |
Why?
| | Environmental Exposure | 1 | 2019 | 372 | 0.030 |
Why?
| | Feminization | 1 | 2015 | 6 | 0.030 |
Why?
| | Protein Kinase C | 2 | 1994 | 273 | 0.030 |
Why?
| | Altitude | 1 | 2019 | 432 | 0.030 |
Why?
| | Epoxy Compounds | 1 | 2015 | 31 | 0.030 |
Why?
| | Mitogen-Activated Protein Kinases | 1 | 1996 | 278 | 0.030 |
Why?
| | Carnitine O-Palmitoyltransferase | 1 | 2015 | 43 | 0.030 |
Why?
| | Heterografts | 1 | 2015 | 117 | 0.030 |
Why?
| | Ischemia | 2 | 1996 | 362 | 0.030 |
Why?
| | Proteins | 2 | 1997 | 908 | 0.030 |
Why?
| | Colorado | 2 | 2015 | 4099 | 0.030 |
Why?
| | Disease-Free Survival | 1 | 2016 | 620 | 0.030 |
Why?
| | Cell Movement | 1 | 2019 | 868 | 0.030 |
Why?
| | T-Lymphocytes, Helper-Inducer | 1 | 1995 | 127 | 0.030 |
Why?
| | Risk Factors | 2 | 2019 | 8628 | 0.030 |
Why?
| | Positron-Emission Tomography | 1 | 2015 | 259 | 0.030 |
Why?
| | Immunohistochemistry | 2 | 2010 | 1629 | 0.030 |
Why?
| | Least-Squares Analysis | 1 | 2014 | 70 | 0.030 |
Why?
| | Mice, Nude | 1 | 2015 | 630 | 0.030 |
Why?
| | Needles | 1 | 2014 | 49 | 0.030 |
Why?
| | SEER Program | 1 | 2014 | 196 | 0.030 |
Why?
| | Cytochrome P-450 CYP3A | 1 | 2013 | 61 | 0.030 |
Why?
| | Radiotherapy | 1 | 2014 | 176 | 0.030 |
Why?
| | Estrogens | 1 | 2015 | 312 | 0.030 |
Why?
| | T-Lymphocyte Subsets | 1 | 1995 | 383 | 0.030 |
Why?
| | Child | 3 | 2022 | 18404 | 0.030 |
Why?
| | Phosphorylation | 3 | 2008 | 1569 | 0.030 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 1995 | 339 | 0.030 |
Why?
| | Lipid Metabolism | 1 | 2015 | 444 | 0.030 |
Why?
| | Oxidation-Reduction | 1 | 2015 | 923 | 0.020 |
Why?
| | Equipment Design | 1 | 2014 | 508 | 0.020 |
Why?
| | Reoperation | 1 | 2014 | 514 | 0.020 |
Why?
| | Population Surveillance | 1 | 2014 | 392 | 0.020 |
Why?
| | Life Style | 1 | 2013 | 430 | 0.020 |
Why?
| | Anxiety | 1 | 2017 | 840 | 0.020 |
Why?
| | Atrophy | 1 | 2010 | 152 | 0.020 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2011 | 309 | 0.020 |
Why?
| | Cell Separation | 1 | 2011 | 291 | 0.020 |
Why?
| | Feasibility Studies | 1 | 2013 | 739 | 0.020 |
Why?
| | Cohort Studies | 1 | 2020 | 4894 | 0.020 |
Why?
| | Apoptosis | 1 | 2019 | 2362 | 0.020 |
Why?
| | Aging | 2 | 2010 | 1618 | 0.020 |
Why?
| | Microscopy, Fluorescence | 1 | 2011 | 396 | 0.020 |
Why?
| | Social Support | 1 | 2013 | 528 | 0.020 |
Why?
| | Incidence | 1 | 2015 | 2311 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 1 | 2020 | 3039 | 0.020 |
Why?
| | Socioeconomic Factors | 1 | 2013 | 1077 | 0.020 |
Why?
| | Imaging, Three-Dimensional | 1 | 2012 | 510 | 0.020 |
Why?
| | Nephrolithiasis | 1 | 2009 | 10 | 0.020 |
Why?
| | DNA Primers | 1 | 2010 | 510 | 0.020 |
Why?
| | Metaplasia | 1 | 2009 | 54 | 0.020 |
Why?
| | Prostatitis | 1 | 2009 | 18 | 0.020 |
Why?
| | Tumor Stem Cell Assay | 1 | 2008 | 33 | 0.020 |
Why?
| | Adaptation, Psychological | 1 | 2013 | 547 | 0.020 |
Why?
| | NADPH Oxidases | 1 | 2009 | 120 | 0.020 |
Why?
| | Anoikis | 1 | 2008 | 31 | 0.020 |
Why?
| | Pilot Projects | 1 | 2013 | 1372 | 0.020 |
Why?
| | Practice Patterns, Physicians' | 1 | 2017 | 1177 | 0.020 |
Why?
| | Genes, Immediate-Early | 1 | 2008 | 15 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 923 | 0.020 |
Why?
| | Hypoglycemic Agents | 1 | 2015 | 1008 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-jun | 1 | 2008 | 47 | 0.020 |
Why?
| | Receptors, Androgen | 1 | 2009 | 131 | 0.020 |
Why?
| | DNA, Mitochondrial | 1 | 2009 | 182 | 0.020 |
Why?
| | Gonadal Steroid Hormones | 1 | 2009 | 124 | 0.020 |
Why?
| | Blotting, Western | 1 | 2010 | 1147 | 0.020 |
Why?
| | Glutathione | 1 | 2009 | 293 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-myc | 1 | 2008 | 115 | 0.020 |
Why?
| | MAP Kinase Signaling System | 1 | 2008 | 276 | 0.020 |
Why?
| | Base Sequence | 1 | 2010 | 2114 | 0.020 |
Why?
| | RNA, Small Interfering | 1 | 2008 | 535 | 0.020 |
Why?
| | Models, Animal | 1 | 2008 | 344 | 0.020 |
Why?
| | Phosphotyrosine | 2 | 1996 | 33 | 0.020 |
Why?
| | Guinea Pigs | 1 | 2005 | 136 | 0.020 |
Why?
| | Biomarkers | 1 | 2015 | 3408 | 0.020 |
Why?
| | Equol | 1 | 2005 | 2 | 0.020 |
Why?
| | Chinchilla | 1 | 2005 | 37 | 0.020 |
Why?
| | Stress, Psychological | 1 | 2013 | 944 | 0.020 |
Why?
| | Swine | 1 | 2008 | 700 | 0.020 |
Why?
| | Antioxidants | 1 | 2009 | 530 | 0.020 |
Why?
| | Infant, Newborn | 1 | 2015 | 5043 | 0.020 |
Why?
| | Diagnosis, Differential | 1 | 2009 | 1342 | 0.010 |
Why?
| | Bladder Exstrophy | 1 | 2004 | 15 | 0.010 |
Why?
| | Tomography, X-Ray Computed | 1 | 2014 | 2279 | 0.010 |
Why?
| | Acid-Base Equilibrium | 1 | 2004 | 29 | 0.010 |
Why?
| | Bicarbonates | 1 | 2004 | 41 | 0.010 |
Why?
| | Hypoxia | 1 | 2010 | 957 | 0.010 |
Why?
| | Meat | 1 | 2005 | 87 | 0.010 |
Why?
| | Referral and Consultation | 1 | 2009 | 632 | 0.010 |
Why?
| | Meningomyelocele | 1 | 2004 | 55 | 0.010 |
Why?
| | Body Height | 1 | 2004 | 180 | 0.010 |
Why?
| | Infant | 1 | 2015 | 7959 | 0.010 |
Why?
| | Child, Preschool | 1 | 2015 | 9108 | 0.010 |
Why?
| | Bone Density | 1 | 2004 | 432 | 0.010 |
Why?
| | RNA, Messenger | 1 | 2008 | 2552 | 0.010 |
Why?
| | Neoplasms | 1 | 2013 | 2097 | 0.010 |
Why?
| | Gene Expression Regulation | 1 | 2008 | 2319 | 0.010 |
Why?
| | Mutation | 1 | 2009 | 3344 | 0.010 |
Why?
| | Neurons | 1 | 2005 | 1279 | 0.010 |
Why?
| | GRB2 Adaptor Protein | 1 | 1996 | 12 | 0.010 |
Why?
| | Proto-Oncogene Proteins c-raf | 1 | 1996 | 43 | 0.010 |
Why?
| | Sialoglycoproteins | 1 | 1996 | 159 | 0.010 |
Why?
| | JNK Mitogen-Activated Protein Kinases | 1 | 1996 | 144 | 0.010 |
Why?
| | Receptors, Interleukin-1 | 1 | 1996 | 228 | 0.010 |
Why?
| | Interleukin 1 Receptor Antagonist Protein | 1 | 1996 | 254 | 0.010 |
Why?
| | Lymphocyte Count | 1 | 1995 | 133 | 0.010 |
Why?
| | Densitometry | 1 | 1994 | 29 | 0.010 |
Why?
| | Phosphotransferases | 1 | 1994 | 25 | 0.010 |
Why?
| | Precipitin Tests | 1 | 1994 | 88 | 0.010 |
Why?
| | CD4 Lymphocyte Count | 1 | 1995 | 257 | 0.010 |
Why?
| | Injections, Intraperitoneal | 1 | 1994 | 99 | 0.010 |
Why?
| | Ornithine Decarboxylase | 1 | 1994 | 9 | 0.010 |
Why?
| | Genes, myc | 1 | 1994 | 46 | 0.010 |
Why?
| | Molecular Weight | 1 | 1994 | 331 | 0.010 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 1994 | 318 | 0.010 |
Why?
| | Immunoblotting | 1 | 1994 | 283 | 0.010 |
Why?
| | Cytosol | 1 | 1994 | 208 | 0.010 |
Why?
| | Substrate Specificity | 1 | 1994 | 352 | 0.010 |
Why?
| | Tyrosine | 1 | 1994 | 214 | 0.010 |
Why?
| | Kinetics | 1 | 1996 | 1551 | 0.010 |
Why?
| | Interleukin-1 | 1 | 1996 | 966 | 0.010 |
Why?
| | Gene Expression | 1 | 1994 | 1421 | 0.010 |
Why?
| | Antibodies, Monoclonal | 1 | 1994 | 1262 | 0.000 |
Why?
| | T-Lymphocytes | 1 | 1995 | 1736 | 0.000 |
Why?
|
|
Maroni's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|